Form 4 for TBPH Theravance Biopharma, Inc.
Accepted 2023-03-03 00:00:00 ET · period of report 2023-03-01 · accession 0001415889-23-004277 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-03 | 2023-03-01 | TBPH | Winningham Rick E | CEO, Dir | A - Grant | $0.00 | +330.0K | 1.64M | +25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-03-01 | A | A | 330,000 | $0.00 | 1,643,377 | D | — | — | (F1) On March 1, 2023, the reporting person was granted 330,000 RSUs. 165,000 RSUs are subject to service-based vesting conditions and the remaining 165,000 RSUs vest based on the achievement of share price appreciation targets as well as continued employment. |